Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients

NCT05912816 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Upper Urinary Tract Urothelial Carcinoma
Kidney Preservation
HER-2 ADC
PD-1antibody

Interventions

DRUG: RC48 Combined With Tislelizumab

Sponsor

RenJi Hospital

Collaborators

[object Object]
[object Object]
[object Object]